Proxima Joins Truthset Data Collective, Validating Best‑in‑Class Data Quality
Validated. Verified. Vetted. Proxima's data platform is now Truthset-approved and meets the industry's highest standard for accuracy, quality, and reliability.
Share
Truthset, the leading data validation company, formed the Data Collective to provide an agnostic, independent platform for businesses to share and benchmark the accuracy of their marketing data. As data-driven marketing has become crucial for brands to reach consumers, the Data Collective is a multi-sourced arbiter to standardize data accuracy for audience targeting and media measurement.
Launched in 2022, Proxima is building an AI-powered marketing platform trained on the world's largest DTC commerce graph. Their predictive models analyze over $20B in eCommerce transactions and 64 million anonymized shopper profiles to help marketers reach and convert high-value customers across their advertising ecosystem with unparalleled efficiency.
As a newly minted member of the Truthset Data Collective, Proxima has received the highest caliber of data validation, ensuring its unique dataset meets the industry-leading standards of quality and accuracy.
"Brands and agencies are increasingly prioritizing retail and transaction data across their marketing channels to drive better outcomes," said Alex Song, CEO of Proxima. 'Proxima has unlocked a significant and highly valuable area of DTC commerce through our unique data intelligence, empowering marketers to achieve new heights of performance. Joining the Truthset Data Collective is essential to our vision as it reinforces our commitment to providing high-quality, trustworthy data intelligence that drives better results for our partners and the industry."
'Proxima's approach to DTC commerce delivers a unique set of data intelligence solutions to the market,' said Scott McKinley, CEO of Truthset. 'We're excited to welcome them to the Data Collective and look forward to collaborating to raise the bar for data accuracy across the marketing industry.'
This partnership reinforces Proxima's commitment to data quality, giving its partners confidence that its consumer datasets are reliable, accurate, and effective in supporting the precision and profitability of their data-driven marketing strategies.
Proxima's induction into the Data Collective follows the recent launch of their DTC segments for programmatic advertising, now available in the data marketplaces of popular DSPs including The Trade Desk and Yahoo. Programmatic advertisers and agency traders can now seamlessly activate digital ad campaigns against Proxima's high-value, unmodeled, 100% deterministic DTC consumer segments within their preferred DSP.
About Proxima
Proxima is transforming the consumer technology landscape and giving B2C businesses the data they need to make informed decisions that drive superior marketing performance. Proxima is a first-of-its-kind data intelligence solution that securely leverages artificial intelligence and a proprietary data network to enable businesses to achieve greater scale, efficiency, and financial success across their marketing stack. Their mission is to be the essential intelligence platform for powering marketing performance for all consumer businesses. Learn more about Proxima here.
About Truthset
Truthset is the leading consumer data validation company. The company helps brands build trust in data, and improve the performance of any data-driven decision. Truthset does not sell data and is not a data broker; it compiles a likelihood of truth for any individual record that can be used to validate the accuracy of data and power more accurate consumer interactions. Truthset was founded in 2019 by industry veterans from Nielsen, Salesforce, LiveRamp, and Procter & Gamble. Truthset is funded by venture investors. The company is headquartered in San Francisco. Learn more about Truthset here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
a day ago
- Yahoo
Trump Media Delays Registration for Bitcoin ETF
President Donald Trump's media company filed an updated application for its Truth Social Bitcoin ETF last week, delaying its launch date amid caution toward crypto at the Securities and Exchange Commission. The updated filing, which was initially submitted in June, still does not include details such as a fee or ticker symbol. Some say the fund, which will directly track the price of bitcoin, might struggle to differentiate itself. 'Bitcoin is effectively digital gold. [It's] not really being used for transactions the way you know currencies are,' said Jeff DeMaso, founder of the newsletter The Independent Vanguard Advisor. 'How much appetite is there for different flavors of digital gold?' READ ALSO: These ETFs Are Going Nuclear and Are Cyclical ETFs Worth the Boom and Bust? The Bit(coin) Of Your Own Drum Trump's bitcoin ETF is one of three filings from Trump Media, which owns his social media platform Truth Social, the other two being the Truth Social Crypto Blue Chip ETF and the Truth Social Bitcoin and Ethereum ETF. Josh Barone, wealth manager at Savvy Advisors, said that having both a bitcoin fund and a more diversified crypto index fund taps into two distinct markets: the 'ideological retail investor' who wants a Trump-approved product, and the 'broader, crypto-curious crowd.' He added that 'fixed supply dynamics, increasing institutional adoption, and a maturing ETF market' have lowered bitcoin's barriers to entry for investors who wouldn't otherwise get into crypto. Still, DeMaso says the fund is likely to blend into the background compared to other, more established funds. 'I would fully expect the iShares, the Fidelitys of the world to kind of continue to take the bulk of the assets,' he said. 'The ETF space is really winner-takes-all, and that race has already started.' Invest in Gold Thor Metals Group: Best Overall Gold IRA Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase American Hartford Gold: #1 Precious Metals Dealer in the Nation The biggest players in the bitcoin ETF space are: The iShares Bitcoin Trust ETF (IBIT), which has over $88 billion in assets; Fidelity's Wise Origin Bitcoin Fund (FBTC), which has $23 billion in assets; And Grayscale's Bitcoin Trust ETF (GBTC), which has $21 billion in assets. Crypto-Curious. At least in the short run, the product will be successful because of Trump's political base, the fund's media attention and pro-crypto policy tailwinds, Barone said. Long-term viability, however, will depend on the success of its 'initial adoption phase, followed by consistent execution, transparency, and competitive pricing,' he said. 'The branding alone will attract a segment of the market that might otherwise avoid crypto entirely.' This post first appeared on The Daily Upside. To receive exclusive news and analysis of the rapidly evolving ETF landscape, built for advisors and capital allocators, subscribe to our free ETF Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in pre-market on Aug. 19, 2025. FDA Gives Green Signal to Wegovy for MASH On Friday, the company announced that Wegovy had been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. The treatment is to be used in combination with a reduced-calorie diet and increased physical activity. First GLP-1 Therapy Approved for MASH The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the ESSENCE Trial The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy's superior efficacy over placebo in improving liver fibrosis. Notably, 62.9% of participants on Wegovy achieved the resolution of steatohepatitis with no worsening of fibrosis compared to 34.3% on placebo. About 36.8% achieved improvement in liver fibrosis without worsening steatohepatitis after 72 weeks versus 22.4% on placebo. The second phase of the trial is expected to conclude in 2029. Market Impact Novo Nordisk confirmed that Wegovy would be immediately available in the United States for MASH treatment. Currently, the only other FDA-approved therapy for MASH is Madrigal Pharmaceuticals' Rezdiffra, which received clearance in 2024. This means Novo Nordisk's Wegovy should make a killing from businesses generated from MASH treatment. NVO-Heavy ETFs in Focus Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) that are heavy on Novo Nordisk. The NVO has solid exposure to ETFs like Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and VanEck Pharmaceutical ETF PPH. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report VanEck Pharmaceutical ETF (PPH): ETF Research Reports Amplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
